Lumosa was invited to the tenth Stroke Treatment Academic Industry Roundtable (STAIR X) held on October 23-24 in Washington D.C., USA, where top scientists and specialists gather to publish the latest research on cerebral stroke. Applications of neuroprotection agents on acute ischemic stroke were discussed during the STAIR conference. Neuroprotectants may protect the brain from ischemia and can be combined with thrombectomy to extend the "Golden Hour" and enhance treatment effect. Lumosa's LT3001 possess thrombolytic and neuroprotective functions and is currently under Phase 1 trial in the US.